AEROSPORIN Drug Patent Profile
When do Aerosporin patents expire, and when can generic versions of Aerosporin launch?
Aerosporin is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in AEROSPORIN is polymyxin b sulfate. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aerosporin
A generic version of AEROSPORIN was approved as polymyxin b sulfate by FRESENIUS KABI USA on January 10th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AEROSPORIN?
- What are the global sales for AEROSPORIN?
- What is Average Wholesale Price for AEROSPORIN?
Summary for AEROSPORIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Patent Applications: | 67 |
| DailyMed Link: | AEROSPORIN at DailyMed |
US Patents and Regulatory Information for AEROSPORIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | AEROSPORIN | polymyxin b sulfate | INJECTABLE;INJECTION | 062036-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
